What Mucosal Healing Partners Are Saying

“Boehringer Inglheim is proud to join forces with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and other esteemed organizations to better define and measure healing in inflammatory bowel diseases. By improving and standardizing how disease stage is determined, the life scientific community will be better equipped to develop new therapies for patients in need.  Boehringer Ingelheim is deeply committed to collaboration and believes that bringing together the best minds will foster true innovation and breakthroughs.”  

“Bristol Myers Squibb is proud to join the Foundation for the National Institutes of Health’s Biomarker Consortium and work alongside public, private and academic partners to drive an improved understanding of mucosal inflammation and what constitutes successful mucosal healing, which may ultimately lead to improved therapies for patients. At Bristol Myers Squibb, partnership and collaboration are essential to how we transform care, and this project exemplifies our focus on contributing to scientific advancements with the goal of developing effective therapies for patients with inflammatory bowel disease.”

“The Crohn’s & Colitis Foundation is dedicated to accelerating the pace of research to improve the lives of patients living with inflammatory bowel disease (IBD), including ulcerative colitis. After participating in the planning of this project, we are eager to continue to be part of this important effort, given the exceptional alignment with the Foundation’s desire to see therapies advance more quickly to patients.  This project represents a critical step to enable the research needed to develop a precision medicine approach for IBD and may also have important direct implications for clinical management.”

“Lilly is committed to developing effective and safe medicines for inflammatory bowel disease (IBD) to improve the lives of people with these chronic autoimmune diseases. We are proud to support the Mucosal Healing Project, recognizing that it will raise the bar in the treatment of ulcerative colitis by more clearly defining the potential role of healing the mucous membranes that become damaged as an important therapeutic target for people living with IBD.”

“Improving the development of novel therapeutics for people with ulcerative colitis requires a detailed understanding of disease progression at the cellular and molecular level. The Mucosal Healing project leverages the resources and expertise of a diverse group of partners to establish a standard definition for measuring tissue healing that signals disease remission. I am confident that these efforts will advance the field to ultimately deliver better long-term outcomes for patients.”

“Janssen Immunology is proud to partner with other drug developers, patient groups, leading academic and government experts in ulcerative colitis, as well as regulators and public health agencies to establish a common and harmonized method to evaluate mucosal healing in UC. This collaboration through the Foundation for the National Institutes of Health (FNIH) demonstrates our shared commitment to patients. We believe that improved, standardized histologic evaluation in UC will enable improved drug trials and identification of therapies that promote microscopic healing of diseased tissue.”

“The Kenneth Rainin Foundation is delighted to be a partner with the FNIH Biomarkers Consortium Mucosal Healing for UC Project.  There is a clear unmet need for ulcerative colitis patients that makes this a crucial piece of work within the biomedical research community in IBD.  The FNIH has a great history of bringing thought and financial partners together to solve a variety of health challenges.  The Kenneth Rainin Foundation is glad to be part of this working group in order to develop new treatments for IBD patients.”

“Takeda is pleased to continue its long-standing collaboration with the FNIH Inflammation and Immunity Biomarkers group to develop and qualify a histology-based method for measuring mucosal healing in ulcerative colitis.  Standardizing this method will improve our understanding of patient disease status and the impact of therapy.  This work will lead to more informative and efficient clinical studies and increase the probability for development of new therapies to treat patients living with ulcerative colitis.”